Treanda (bendamustine)

What is Treanda?

Treanda®, the trade name of bendamustine hydrochloride, is FDA approved for the treatment of indolent B-cell non-Hodgkin’s lymphoma that has not responded well to rituximab treatment. Treanda is also FDA approved for use in the treatment chronic lymphocytic leukemia (CLL).

How does it work?

Treanda is an alkylating agent that works to stop the growth of cancer cells by attaching itself to DNA and interfering with DNA replication.

How is it administered?

Treanda is administered intravenously through 60-minute infusion. A needle is put into a vein and the drug is delivered to the body during the infusion process.

How long does it take?

As mentioned above, a single dose can be administered in 60 minutes. However, multiple doses are required for a complete treatment regimen. One treatment cycle is 21 days and Treanda is administered on days 1 and 2 of each cycle. The number of cycles required varies from patient to patient, with a maximum of 8 cycles.

Is Treanda Effective?

In a clinical study assessed by a blinded independent review committee Treanda produced a robust response when used as a single agent to treat indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. In addition, Treanda maintained duration of response, which is the amount of time the response to treatment lasts. In this study, overall response rates were 74% and the median duration of response was 9.2 months.

Side Effects

The following serious adverse reactions have been associated with Treanda: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation. Some of these reactions have been fatal, including myelosuppression, infections, and SJS/TEN (when Treanda was administered concomitantly with allopurinol and other medications known to cause SJS/TEN). Patients should be monitored closely for these reactions and treated promptly if any occur. Adverse reactions may require interventions such as decreasing the dose of Treanda, or withholding or delaying treatment. Myelosuppression is frequently severe and should be expected when treating patients with Treanda.

Treanda is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using Treanda.

The most common non-hematologic adverse reactions associated with Treanda (frequency ≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common hematologic abnormalities associated with Treanda (frequency ≥15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.

Dive Deeper

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap